newsfilter
← Latest News
GlobeNewswire·

Amryt Presents Data for Mycapssa® (oral octreotide) from OPTIMAL and MPOWERED Phase 3 Trials at ENDO 2022

Amryt Presents Data for Mycapssa® (oral octreotide) from OPTIMAL and MPOWERED Phase 3 Trials at ENDO 2022 Data from the MPOWERED OLE and first presentation of open-label extension (OLE) data from 2nd year of OPTIMAL demonstrate the long-term safety a